Intel
INTC
ASML Holding
ASML
Disney
DIS
4
Apple
AAPL
5
Salesforce
CRM
US Stock MarketDetailed Quotes
AGEN Agenus
- 1.730
- -0.050-2.81%
Close Mar 18 16:00 ET
43.78MMarket Cap-0.16P/E (TTM)
1.792High1.641Low573.23KVolume1.730Open1.780Pre Close978.61KTurnover2.32%Turnover RatioLossP/E (Static)25.31MShares19.68852wk High-0.13P/B42.77MFloat Cap1.64152wk Low--Dividend TTM24.72MShs Float8419.554Historical High--Div YieldTTM8.48%Amplitude1.641Historical Low1.707Avg Price1Lot Size
Agenus Stock Forum
Sign in to post a comment
$Agenus (AGEN.US)$
Can Agenus' Cancer Therapy Breakthrough Transform "Cold Tumor" Treatment?
Can Agenus' Cancer Therapy Breakthrough Transform "Cold Tumor" Treatment?
1
$Agenus (AGEN.US)$
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
Wednesday, 26th February at 4:48 pm
Agenus Inc. (NASDAQ: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.
Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune a...
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
Wednesday, 26th February at 4:48 pm
Agenus Inc. (NASDAQ: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.
Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune a...
1
$Agenus (AGEN.US)$
Can This Novel Triple Immunotherapy Crack the Code for Treatment-Resistant Gastric Cancer?
Can This Novel Triple Immunotherapy Crack the Code for Treatment-Resistant Gastric Cancer?
$Agenus (AGEN.US)$
Clinical Data Alert: Agenus Unveils Dual Cancer Treatment Results for Breakthrough BOT/BAL Therapy
Clinical Data Alert: Agenus Unveils Dual Cancer Treatment Results for Breakthrough BOT/BAL Therapy
$Incyte (INCY.US)$ $Agenus (AGEN.US)$ Reuters· 2 mins ago
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEV...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEV...
41
15
5
$Agenus (AGEN.US)$Businesswire· 15 mins ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.
These findings further reinforce the consistency of the BOT/BAL combination, which has already shown activity and ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.
These findings further reinforce the consistency of the BOT/BAL combination, which has already shown activity and ...
1
4
$Agenus (AGEN.US)$
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
Wednesday, 29th January at 12:37 pm
Agenus Inc. (NASDAQ: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.
These...
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
Wednesday, 29th January at 12:37 pm
Agenus Inc. (NASDAQ: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.
These...
2
$Agenus (AGEN.US)$
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Wednesday, 22nd January at 2:48 pm
• Results from two independent neoadjuvant studies in the U.S. and Europe, enrolling more than 80 patients, underscore BOT/BAL's potential to enable chemo-free and non-operative approaches in colorectal cancer (CRC).
• New randomized Phase 2 results in over 230 patients with refractory MSS mCRC, consistent with Pha...
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Wednesday, 22nd January at 2:48 pm
• Results from two independent neoadjuvant studies in the U.S. and Europe, enrolling more than 80 patients, underscore BOT/BAL's potential to enable chemo-free and non-operative approaches in colorectal cancer (CRC).
• New randomized Phase 2 results in over 230 patients with refractory MSS mCRC, consistent with Pha...
1
No comment yet
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Fed’s March rate decision nears: Market pivot ahead?
How will the Fed's rate decision impact short-term trends in U.S. stocks? How would you reposition your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025
71156064 : Might as well be.